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Abstract
Background: Osteoprotegerin (OPG) is a member of the tumor necrosis factor superfamily. 
Recent evidence supports a relationship between serum OPG level and atherosclerosis. The 
aim of this study was to evaluate the possible association of OPG with the presence of coronary 
artery disease (CAD), its severity and prognosis in patients with chest pain and suspected 
coronary stenosis. 
Methods: In this cross-sectional analytic study, 180 candidates of elective coronary artery an-
giography were recruited. Serum level of OPG was measured by ELISA method in all patients 
and its relation with presence and severity of CAD based on a coronary atherosclerosis score 
(CAS) was assessed. Patients were followed for a mean period of about 24 ± 3.2 months and 
the relationship between OPG levels and future cardiac events were evaluated. 
Results: The mean serum level of OPG was 1637 ± 226 pg/mL in those with CAD and 1295 ±  
± 185 pg/mL (nonparametric p = 0.001) in those without it. There was a significant direct 
correlation between the level of serum OPG and CAS (rho = 0.225, p = 0.002). The optimal 
cut-off point for predicting a  significant coronary artery obstruction was a  serum level of  
³ 1412 pg/mL with a sensitivity and specificity of 60% and 57.8%, respectively. Major adverse 
cardiac events (MACE) including cardiovascular death, admission with acute coronary syn-
drome, or heart failure, was significantly higher in those with higher OPG levels (22 [34.3%] 
vs. 15 [16%], p = 0.012).
Conclusions: There was a direct and significant correlation between the serum level of OPG 
and CAS. MACE occurred more commonly in those with higher baseline OPG levels. (Cardiol J 
2013; 20, 3: 261–267)
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Introduction
The receptor activator of nuclear factor-Kb 
ligand (RANKL) is recently known as an impor-
tant factor in osteoclastogenesis. Osteoprotegerin 
(OPG), a member of the tumor necrotic factor 
receptor family and a decoy receptor for RANKL 
plays its role in bone remodeling by blocking 
RANKL-ligand [1]. Actually it is the indirect inhi-
bitor of the osteoclasts. 
Osteoprotegerin is expressed in vivo by en-
dothelial cells, vascular smooth muscle cells, and 
osteoblasts [2]. High serum OPG levels may lead 
to vascular calcification, formation of atheroscle-
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rotic plaques, increasing blood pressure, and car-
diovascular diseases [3]. Recent studies proposed 
a relationship between the serum OPG level with 
prevalence and severity of coronary artery disease 
(CAD) [4, 5], the degree of arterial calcification 
[6–8] and presence of unstable coronary plaques 
[9, 10]. However, the predictive value of OPG in 
determining CAD, compared with simple diagno-
stic tools like exercise tolerance test (ETT) was 
not studied before.
In this study we aimed to investigate the 
serum level of OPG in patients who referred to 
our hospital with chest pain and were candidates 
for coronary angiography. We tried to determine 
whether the serum OPG level could be used as 
a diagnostic tool for identifying the presence and 
severity of CAD or not. Almost all of the previous 
studies have used the number of stenotic coronary 
arteries as a marker of CAD severity, however, 
we used a  coronary artery severity score [11] 
to evaluate more accurately the possible rela-
tionship between CAD severity and OPG levels. 
Also we evaluated the prognostic impact of OPG 
level in this cohort of our patients during midterm 
follow-up period.
Methods
This cross-sectional study was conducted in 
Shahid-Madani Heart Hospital of Tabriz with the 
approval of Scientific and Ethical Review Boards 
of Tabriz University of Medical Sciences, Tabriz, 
Iran. Written informed consent was obtained from 
all patients.
Participants
Between April 2008 and April 2009, 180 pa-
tients who fulfilled the criteria for suspected stable 
angina pectoris based on history and/or positive 
provocational tests (ETT, stress echocardiography 
or myocardial perfusion imaging) and were candi-
dates for diagnostic coronary angiography were 
enrolled in the study. Patients with previously 
documented CAD, those with history of myocar-
dial infarction, unstable angina, or coronary artery 
bypass graft, or those with any specific condition 
which could affect on the serum levels of OPG 
(including proved malignancy, serum creatinine 
> 2 mg/dL, treatment with corticosteroids or im-
munosuppressant drugs and being menopaused) 
were excluded from the study. Demographic data 
and distribution of risk factors were assessed 
through an interview preceding the coronary 
angiography. Diabetes was considered present if 
a patient was treated with insulin or oral agents or 
had a fasting glucose level ≥ 126 mg/dL. Hyperten-
sion was defined by current use of antihypertensive 
treatment, systolic blood pressure ≥ 140 mm Hg 
or diastolic blood pressure ≥ 90 mm Hg, or a com-
bination of these. Hyperlipidemia was defined as 
total cholesterol level ≥ 240 mg/dL, the current 
use of lipid-lowering treatment, or both. Patients 
were followed for a mean period of 24 ± 3.2 months 
with telephone call or outpatient visit to determine 
the future cardiac events or mortality. All cause 
death, cardiovascular death, any admission with 
acute coronary syndrome (ACS) or heart failure 
(HF) were recorded.
Angiography and coronary  
atherosclerosis scoring
For angiography we used the usual method 
with 4 views for left coronary artery and 2 views 
for right coronary arteries. The severity of vascu-
lar obstruction was determined according to the 
Coronary Atherosclerosis Scoring (CAS) system 
described by Gensini [11]. 
In CAS system, the entire coronary tree was 
divided into 8 segments: main left coronary artery 
(MLCA), left anterior descending artery (LAD), 
proximal segment (first one-third) of the septal 
branch of LAD, proximal segment of the diagonal 
branch of the LAD, circumflex artery, proximal 
segment of obtuse marginal branch of circumflex 
artery, right coronary artery, and proximal segment 
of the posterior descending artery. The percentage 
of luminal obstruction in the coronary arteries’ cir-
culation was measured. The severity of obstruction 
was determined according to the following scores: 
Score 1 for plaques with < 50% luminal narrowing, 
score 2 for 50–74% reduction in luminal diameter, 
score 3 for 75–99% reduction in luminal diameter 
and score 4 for total occlusion. 
The patients were categorized into 2 groups 
according to the findings of angiographic evalua-
tion: a group of 135 patients with CAD, and a group 
consisted of 45 patients without any evidence of 
CAD in angiography. 
Laboratory experiments
Blood samples were drawn from all partici-
pants at the morning of the day they scheduled to 
undergone angiography, after 12 hours of fasting. 
The blood samples were centrifuged and the sera 
were freezed at –70oC. The concentration of both 
total cholesterol and triglyceride were measured 
using Bio Systems spectrophotometric assay kits. 
High- and low-density lipoprotein was measured 
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for all sera. The serum OPG level was measured 
using the enzyme-linked immunosorbent assay 
(ELISA). 
Statistical analysis
The patients’ characteristics including age, 
sex, body mass index (BMI), familial history of 
CAD, hyperlipidemia, hypertension, diabetes 
mellitus, history of smoking, and recent therapy 
with statins were collected and compared among 
two groups with and without CAD. 
We used the SPSS software version 16 for 
statistical analysis. The data were provided as mean 
± SD for quantitative variables, and frequency (%) 
for the qualitative variables. Quantitative variables 
were compared among groups using Independent 
T-test, Mann-Whitney U-test, or one-way ANOVA 
and Tukey test. The quantitative (categorical) 
variables were compared using contingency tab-
les, and by c2 test, and Fisher’s exact test, when 
needed. Receiver operating characteristics (ROC) 
curve and coordinates of the curve were used in 
order to determine the cutoff point of serum OPG 
level in identifying patients with CAD. Logistic 
regression was used to determine the indepen-
dent factors. P ≤ 0.05 was considered statistically 
significant. The sensitivity, specificity, positive 
predictive value (PPV), negative predictive value 
(NPV), and accuracy of the serum OPG level was 
calculated separately. 
Results
One hundred-eighty subjects were categorized 
according to the findings of angiographic study 
into two groups: a group of 135 (75%) patients 
with CAD, and a  group consisted of 45 (25%) 
patients without CAD in angiography. Regarding 
the severity of CAD, 40 (22.2%) subjects had 
single vessel disease (SVD), 54 (30%) cases had 
2 vessels disease (2VD), 41 (22.8%) patients had 
3 vessels disease (37 cases; 20.6%) or narrowing 
of the MLCA with or without other branch stenosis 
(4 cases; 2.2%). The mean CAD-score was 46.7 ± 
± 4.1 (median = 46). The clinical and laboratory 
characteristics of the patients in both groups were 
summarized and compared in Table 1. The mean 
age, frequency of male patients and the rate of 
smoking were higher in the CAD group, and the 
mean BMI was higher in the control group. There 
was not statistically significant difference among 
2 groups for other variables. 
There was no significant difference in chole-
sterol or triglyceride or creatinine levels between 
2 groups. The mean serum level of OPG was sig-
nificantly higher among CAD patients compared to 
the others (1637 ± 226 pg/mL in CAD group vs. 
1295 ± 185 pg/mL in control group; p < 0.001). 
In general, ETT was performed in 79 (43.9%) 
patients. ETT was positive in 48 (82.8%) subjects 
of the CAD group, and 13 (61.9%) subjects of the 
Table 1. Clinical and paraclinical characteristics of patients in both groups with and without coronary 
artery disease (CAD).
Characteristics CAD (n = 135) Controls (n = 45) P
Age: mean ± SD (median) 56.7 ± 10.5 (56) 51.3 ± 10.6 (51) 0.002
Male sex 121 (89.6%) 25 (55.6%) < 0.001
Body mass index [kg/m2] 26.6 ± 3.8 (26) 28.4 ± 5.9 (28) 0.016
Familial history of CAD 15 (11.1%) 4 (8.9%) 0.459
Hypertriglyceridemia 39 (28.9%) 8 (17.8%) 0.099
Hypertension 58 (43%) 25 (55.6%) 0.142
Diabetes mellitus 26 (19.3%) 4 (8.9%) 0.106
Current smoking 47 (34.8%) 8 (17.8%) 0.039
Recent therapy with statins 47 (34.8%) 16 (35.6%) 0.928
Serum hemoglobin [mg/dL] 14.1 ± 1.7 (14) 13.7 ± 1.7 (13.5) 0.205
Low-density lipoprotein [mg/dL] 194.6 ± 79.4 (187) 181.9 ± 81.8 (167) 0.363
High-density lipoprotein [mg/dL] 27.5 ± 15.4 (24) 35.6 ± 19.9 (29) 0.094
Total cholestrol [mg/dL] 209.9 ± 65.7 (197) 200.1 ± 66.6 (176) 0.389
Triglyceride [mg/dL] 257.3 ± 64.1 (234) 237.1 ± 74.4 (212) 0.080
Creatinine [mg/dL] 0.9 ± 0.2 (0.9) 0.9 ± 0.2 (0.9) 0.630
Serum osteoprotegerin [pg/mL] 1637 ± 226 1295 ± 185 0.001
264 www.cardiologyjournal.org
Cardiology Journal 2013, Vol. 20, No. 3
control group. The diagnostic value of ETT as com-
pared to angiography was demonstrated in Table 2. 
The area under the ROC curve for the serum OPG 
level in predicting CAD was calculated to be 0.609 
(p = 0.028). The most appropriate cutoff point for 
both patient groups with and without CAD was 
serum OPG level of above 1412 pg/mL. The accu-
racy of serum OPG level (with above mentioned 
cutoff point) in predicting CAD was summarized 
in Table 2. The frequency of patients with serum 
OPG level ≥ 1412 pg/mL was higher in the case 
group compared to the control group (p = 0.038, 
OR = 2.1, 95% CI 1–4.1). This difference remai-
ned statistically significant, when adjusted for age, 
sex, BMI, and the history of smoking (p = 0.042, 
ExpB = 0.52). There was a significant correlation 
between serum level of OPG and CAD-score 
(p = 0.002, rho = 0.225). The mean serum OPG 
level was 1332.3 ± 135.6 pg/mL for patients with 
SVD, 1262.5 ± 121.2 pg/mL for patients with 2VD, 
and 1637.5 ± 163.5 pg/mL for patients with 3VD. 
The difference among 3 groups of patients (SVD, 
2VD, 3VD) was not statistically significant (p = 0.598). 
During a mean period of about 24 ± 3.2 months 
and excluding 22 (12.2%) patients we lost to follow, 
major adverse cardiac events (MACE; cardiovascu-
lar death, admission with ACS or HF) occurred in 
37 (23.4%) patients (15 [16%] in those with OPG 
level less than cut off point and 22 [34.3%] in those 
with OPG levels above cut off limit, p = 0.013). 
Figure 1 shows that most of this difference was 
due to higher frequency of admissions with ACS 
in patients with high OPG levels. Figure 2 shows 
Kaplan-Meier survival curves for patients with 
OPG levels higher or lower than 75th percentile. 
Multivariate Cox analysis showed OPG level and 
positive ETT result as independent predictors of 
time to occurrence of MACE (Table 3). 
Discussion
Our study showed that adding serum OPG me-
asurement to ETT in evaluating patients with chest 
pain and suspected CAD increases its sensitivity 
and NPV. Also we showed that serum OPG level 
is correlated with the severity of atherosclerotic 
coronary involvement as reflected in CAS. Finally 
we showed that patients with higher OPG levels 
have higher MACE rates in midterm follow-up 
mainly due to higher occurrence of ACS related 
to plaques instability.
Jono et al. [5] in their study on 201 patients 
who underwent coronary angiography found 
Table 2. The diagnostic value of exercise tolerance test (ETT) vs. serum osteoprotegerin (OPG) level.
ETT OPG ETT + OPG
True positive 48 (60.8%) 81 (45%) 57 (72.2%)
True negative 8 (10.1%) 26 (14.4%) 4 (5.1%)
False positive 13 (16.5%) 19 (10.6%) 17 (21.5%)
False negative 10 (12.7%) 54 (30%) 1 (1.3%)
Sensitivity 82.8% 60% 98.3%
Specificity 38.1% 57.8% 19.1%
Positive predictive value 79% 81% 77%
Negative predictive value 44.4% 32.5% 80%
Accuracy 70.9% 59.4% 77.2%
Figure 1. The distribution of major adverse cardiovascu-
lar events between groups with osteoprotegerin (OPG) 
levels higher and lower than cut off level; CVD — car-
diovascular death; ACS — acute coronary syndrome; 
HF — heart failure.
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a higher OPG level in CAD patients compared 
to the others. The serum OPG level increased 
along with the increase in the severity of CAD. 
They finally concluded that serum OPG levels 
are associated with the presence and severity of 
CAD, suggesting that OPG may be involved in the 
progression of CAD. In the Copenhagen City Heart 
Study, Mogelvang et al. [12] showed that, after 
multivariate adjustment, for each doubling of the 
plasma OPG concentration, the risk for subclinical 
peripheral atherosclerosis increased by 50%. They 
concluded that OPG is independently associated 
with traditional risk factors of atherosclerosis, 
subclinical peripheral atherosclerosis, and clinical 
atherosclerotic disease such as ischemic heart 
disease and ischemic stroke. Anand et al. [13] 
implemented a study on 510 patients with type 2 
diabetes mellitus without any manifestation in fa-
vor of CAD and showed that the serum OPG level 
could predict both subclinical CAD and near-term 
cardiovascular events. All these studies and many 
similar other reports [9, 14, 15] are strongly su-
pporting an association between CAD and serum 
OPG level. We evaluated its sensitivity in a cohort 
of patients with suspected stable CAD. To the best 
of our knowledge, the applicability of serum OPG 
level as a diagnostic tool in comparison with other 
available modalities were not investigated before. 
According to the cutoff point provided in our 
study, the frequency of patients with high serum 
OPG level (≥ 1412 pg/mL) was demonstrated to 
be higher among the CAD patients compared to 
the control group (even when controlled for age, 
sex, and history of smoking). The sensitivity and 
specificity of serum OPG level in differentiating 
among patient with and without CAD, was mode-
rate (60% and 57.8%, respectively). The ETT was 
implemented for a subgroup of patients based on 
the attending physicians decision. The sensitivity 
of ETT was demonstrated to be 82.8% with a low 
specifity (38.1%) which can be attributed to the 
higher number of patients with normal coronary 
arteries resulted from a long list of our exclusion 
criteria. However the specifity for high OPG level 
was higher than ETT (57.8% vs. 38.1%). The con-
current use of ETT and serum OPG level was also 
studied with the aim to improve the patient selec-
tion for coronary angiography. Although the sens-
Table 3. Multivariate Cox analysis in which continuous covariates including age and body mass index 
were analyzed and interpreted per unit, but the serum osteoprotegerin (OPG) level was analyzed and 
interpreted per cutoff value. However according to the p values, only the OPG level and exercise tole-
rance test (ETT) result was demonstrated to have significant impact on the time of major adverse car-
diovascular events occurrence.
P Hazard ratio (HR) 95% confidence interval for HR
Lower Upper
Age 0.669 1.007 0.974 1.041
Body mass index 0.485 1.031 0.946 1.123
Smoking 0.291 1.586 0.673 3.734
Diabetes 0.236 0.602 0.260 1.394
Male sex 0.634 0.787 0.293 2.110
Hyperlipidemia 0.973 1.015 0.427 2.412
Higher OPG level 0.012 0.039 0.030 0.479
Positive ETT 0.022 0.045 0.030 0.642
Figure 2. Kaplan-Meier event free survival curves for pa-
tients with osteoprotegerin (OPG) levels higher (gray) and 
lower (blue) than 75th percentile value of OPG (1485 pg/mL).
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itivity was increased significantly by this method, 
the specificity was decreased. Interestingly NPV 
was increased to about 80%. If we could prove 
this in larger studies it will help us to find a safe 
and cheap approach compared with scintigraphy 
or computed tomography angiography to evaluate 
the presence and risk of CAD especially in this low 
risk subgroup of patients with higher false positive 
results in conventional diagnostic modalities like 
ETT or myocardial perfusion imaging studies. 
In our study the median of serum OPG level 
was significantly higher among CAD patients com-
pared to the others. Reinhard et al. [16] showed 
that increased OPG level was an independent 
predictor of significant CAD. Some studies have 
reported a direct correlation between OPG level and 
the number of involved coronary arteries [5, 17]. We 
could not show a statistically significant correlation 
between mean serum OPG level and the number of 
involved coronary arteries (SVD, 2VD, 3VD). Pre-
vious studies demonstrated that the CAD scoring 
system is better than categorizing CAD patients 
according to number of involved coronary arteries 
in determining the severity of disease [18]. We 
showed a significant correlation between serum 
OPG level and CAD-score and we believe that CAS 
provides more accurate measurement of coronary 
atherosclerosis burden. 
In our study during a midterm follow-up period 
of about 2 years, MACE, defined as cardiovascular 
death, ACS and HF occurred more commonly in 
patients with higher OPG levels. Most part of 
this difference was related to higher rate of ACS 
in patients with higher serum OPG levels, also 
there was a trend to higher rate of cardiovascular 
death in this group (Fig. 1). Vik et al. [19] followed 
6265 subjects recruited from general population 
with a mean follow-up period of about 10.6 years 
and they found that increase in OPG level was 
associated with an increased future risk of myo-
cardial infarction, total mortality, and mortality of 
ischemic heart disease independent of traditional 
cardiovascular risk factors. Similarly Pederson et 
al. [4] reported increased risk of all-cause mortality, 
cardiovascular mortality and myocardial infarction 
with increasing OPG levels among patients with 
suspected stable angina, but independent effects 
were mainly confined to OPG levels above the 
90th percentile. Higher OPG level was an indepen-
dent predictor of poor cardiac prognosis in patients 
with intermediate coronary lesions [2]. Also serum 
OPG level was a strong predictive of long-term 
mortality and HF development in patients with 
ACS, independent of conventional risk markers 
[20]. One proposed mechanism for this increased 
rate of plaque instability and poor cardiovascular 
outcome is up-regulated expression of OPG in en-
dothelial cells, in the presence of proinflammatory 
cytokines, which in turn increases the expression 
of endothelial cell adhesion molecules, up-regu-
lation of the inflammatory cells and increased 
activity of matrix metalloproteinase which leads to 
degradation of the extracellular matrix and reduced 
thickness of the fibrous cap, the erosion of which 
causes thrombus formation [1].
Limitations of the study
This was a single center study with limited 
sample volume. Non invasive diagnostic modalities 
were not used for all patients and the possibility 
of a selection bias by attending physicians could 
not be ruled out. To exclude possible confounding 
factors in measuring OPG levels we selected a re-
latively low risk group of patients and traditionally 
this may be associated with higher rate of false po-
sitive results in conventional tests. Samples were 
stored at −70oC until analysis, and the possibility 
of protein degradation cannot be excluded.
Conclusions
This study showed that serum OPG level may 
be a simple adjuvant to other noninvasive diag-
nostic modalities of CAD. Higher OPG levels are 
associated with extensive atherosclerosis burden, 
higher rate of plaque instability and cardiovascu-
lar events in midterm follow-up of patients with 
suspected CAD. 
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